Perspective on HIV infection and aging: Emerging research on the horizon

Clinical Infectious Diseases

Volumn 41, Issue 6, 2005, Pages 855-863

  Casau, Nathalie C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PHENAZONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SELEGILINE; ZIDOVUDINE;

AGING; BONE DENSITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE EXACERBATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; EARLY DIAGNOSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNE RESPONSE; MEDICAL RESEARCH; MENTAL DISEASE; METABOLIC DISORDER; NEUROLOGIC DISEASE; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURVIVAL RATE; VIROLOGY;

AGED; AGING; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMEDICAL RESEARCH; HIV INFECTIONS; HUMANS; MIDDLE AGED; RISK FACTORS;

EID: 24644507581     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/432797     Document Type: Review

References (82)

1. Centers For Disease Control and Prevention. HIV/AIDS surveillance report, Vol. 13. Atlanta, GA: Centers For Disease Control and Prevention, 2001.
2. Bureau of HIV/AIDS. HIV prevalence estimates. Florida: Florida Department of Health, 2002.
3. The Florida Division of Disease Control. Surveillance report (hepatitis, HIV/AIDS, STD and TB). Vol. 208. Florida: Florida Department of Health, 2001.
4. Hawaii Department of Health. HIV/AIDS surveillance quarterly report, cases to 31 December 2001. Hawaii: Hawaii Department of Health, 2001.
5. Schable B, Chu S, Diaz T. Characteristics of women 50 years of age or older with heterosexually acquired AIDS. Am J Public Health 1996; 86:1616-8.
6. Stall R, Catania J. AIDS risk behaviors among late middle-aged and elderly Americans: the national AIDS behavioral surveys. Arch Intern Med 1994; 154:57-63.
7. Feldman M. Sex, AIDS and the elderly. Arch Intern Med 1994; 154:19-20.
8. Gerbert B, Maguire B. Are patients talking to their physicians about AIDS? Am J Public Health 1990; 80:467-8.
9. El-Sadr W, Gettler J. Unrecognized human immunodeficiency virus infection in the elderly. Arch Intern Med 1995; 155:184-6.
10. Fagnoni FF, Vescovini R, Passeri G, et al. Shortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging. Blood 2000; 95:2860-8.
11. Negoro S, Hara H, Miyata S, et al. Age-related changes of the function of T cell subsets: predominant defect of the proliferative response in CDS positive T cell subset in aged persons. Mech Ageing Dev 1987; 39:263-79.
12. Bestilny LJ, Gill MJ, Mody CH, Riabowol KT. Accelerated replicative senescence of the peripheral immune system induced by HIV infection. AIDS 2000; 14:771-80.
13. Valdez H, Connick E, Smith KY, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16:1859-66.
14. Negoro S, Hara H, Miyata S, et al. Mechanisms of age-related decline in antigen-specific T cell proliferative response: IL-2 receptor expression and recombinant IL-2 induced proliferative response of purified Tac-positive T cells. Mech Ageing Dev 1986; 36:223-41.
15. Lederman MM, McKinnis R, Kelleher D, et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS 2000; 14:2635-42.
16. Douek DC, McFarland RD, Kelser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396:690-5.
17. Goedert JJ, Kessler CM, Aledort LM, et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989; 321:1141-8.
18. + T-cell counts. J Acquir Immune Defic Syndr 1991; 4:970-5.
19. Gardner LI Jr, Brundage JF, McNeil JG, et al. Predictors of HIV-1 disease progression in early- and late-stage patients: the US Army Natural History Cohort. Military Medical Consortium for Applied Retrovirology. J Acquir Immune Defic Syndr 1992; 5:782-93.
20. Operskalski EA, Stram DO, Lee H, et al. Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. Transfusion Safety Study Group. J Infect Dis 1995; 172:648-65.
21. Rothenberg R, Woelfel M, Stoneburner R, Milberg J, Parker R, Truman B. Survival with the acquired immunodeficiency syndrome: experience with 5833 cases in New York City. N Engl J Med 1987; 317:1297-302.
22. Ship J, Wolff A, Selik R. Epidemiology of acquired immune deficiency syndrome in persons aged 50 years or older. J Acquir Immune Defic Syndr 1991; 4:84-8.
23. Skiest D, Rubinstien E, Carley N, Gioiella L, Lyons R. The importance of comorbidity in HIV-infected patients over 55: a retrospective case-control study. Am J Med 1996; 101:605-11.
24. Ferro S, Salit I. HIV infection in patients over 55 years of age. J Acquir Immune Defic Syndr 1992; 5:348-55.
25. Blaxhult A, Granath F, Lidman K, Giesecke J. The influence of age on the latency period to AIDS in people infected by HIV through blood transfusion. AIDS 1990; 4:125-9.
26. Sutin D, Rose D, Mulvihill M, Taylor B. Survival of elderly patients transfusion related acquired immunodeficiency syndrome. J Am Geriatr Soc 1993; 41:214-6.
27. Bachetti P, Osmond D. Survival patterns of the first 500 patients with AIDS in San Francisco. J Infect Dis 1988; 157:1044-7.
28. Yamashita TE, Phair JP, Munoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15:735-46.
29. Goetz MB, Boscardin WJ, Wiley D, Alkasspooles S. Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning highly active antiretroviral therapy. AIDS 2001; 15:1576-9.
30. Manfredi R, Chiodo F. A case control study of virological and immunological effects of highly active antiretroviral therapy in HIV-infected patients with advanced age. AIDS 2000; 14:1475-7.
31. Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001; 183:1290-4.
32. Tumbarello M, Rabagliati R, Donati K. Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario. AIDS 2003; 17:128-30.
33. Fair Wellons M, Sanders L, Edwards LJ, Bartlett JA, Heald AE, Schmader KE. HIV infection: treatment outcomes in older and younger adults. J Am Geriatr Soc 2002; 50:603-7.
34. Perez JL, Moore RD. Greater effect of highly active antiretroviral therapy on survival in people aged 50 years compared with younger people in an urban observational cohort. Clin Infect Dis 2003; 36:212-8.
35. Sauvageon-Matre H, Bannie F, Tabah I, et al. Pharmacokinetics of zidovudine in AIDS patients: influence of age and hepatic disorders [abstract MBP 323]. In: Program and abstracts of the 5th International Conference on AIDS (Montreal). Ottawa: International Development Research Centre, 1989.
36. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 61:331-9.
37. Knobel H, Guelar A, Valldecillo G, et al. Response to highly active antiretroviral therapy in HIV-1 infected patients aged 60 years or older after 24 months of follow up. AIDS 2001; 15:1591-3.
38. Shah S, McGowan J, Smith S, Blum S, Klein R. Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis 2002; 35:1238-43.
39. Manfredi R. HIV disease and advanced age: an increasing therapeutic challenge. Drugs Aging 2002; 19:647-69.
40. Adler W, Padmavathi V, Chrest F, Dorsey-Cooper B, Winchurch R, Nagel J. HIV infection and aging: mechanisms to explain the accelerated rate of progression in the older patient. Mech Ageing Dev 1997; 96:137-55.
41. Greene JG. Constructing a standard climacteric scale. Maturitas 1998; 29:25-31.
42. Clark R, Cohn SE, Jarek C, et al. Perimenopausal symptomatology among HIV-infected women at least 40 years of age. J Acquir Immune Defic Syndr 2000; 23:99.
43. Clark RA, Bessinger R. Clinical manifestations and predictors of survival among older women infected with HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:341-5.
44. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14:F63-7.
45. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003; 17:1917-23.
46. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S. Reduced bone density in HIV-infected women. AIDS 2004; 18:475-83.
47. NIH Consensus Development Panel on Osteoporosis, Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785-95.
48. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31:257-75.
49. Maschke M, Kastrup O, Esser S, Ross B, Hengge U, Hufnagel A. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly activated antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry 2000; 69:376-80.
50. Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001; 56:257-60.
51. Masliah E, DeTeresa RM, Mallory ME, Hansen LA. Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS 2000; 14:69-74.
52. Lawrence DM, Major EO. HIV-1 and the brain: connections between HIV-1-associated dementia, neuropathology and neuroimmunology. Microbes Infect 2002; 4:301-8.
53. Williams KC, Hickey WF. Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci 2002; 25:537-62.
54. Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998; 51(Suppl 1):S2-17.
55. Esiri MM, Biddolph SC, Morris CS. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry 1998; 65:29-33.
56. Corder EH, Robertson K, Lannfelt L, et al. HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med 1998; 4:1182-4.
57. Janssen RS, Nwanyanwu OC, Selik RM, Stehr-Green JK. Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 1992; 42:1472-6.
58. Chiesi A, Vella S, Dally LG, et al. Epidemiology of AIDS dementia complex in Europe. J Acquired Immune Defic Syndr 1996; 11:39-44.
59. Conigliaro J, Madenwald T, Bryant K, et al. The Veterans Aging Cohort Study: observational studies of alcohol use, abuse, and outcomes among human immunodeficiency virus-infected veterans Alcohol Clin Exp Res 2004; 2:313-21.
60. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
61. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-30.
62. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86:27-31.
63. Hommes MJ, Romijn JA, Endert E, Eeftinck Schattenkerk JK, Sauerwein HP. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991; 40:651-6.
64. Geffner ME, Yeh DY, Landaw EM, et al. In vitro insulin-like growth factor-I, growth hormone, and insulin resistance occurs in symptomatic human immunodeficiency virus-1-infected children. Pediatr Res 1993; 34:66-72.
65. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
66. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998; 351:1881-3.
67. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15:231-9.
68. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors [letter]. Lancet 1998;351:1958.
69. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M. Vascular complications associated with use of HIV protease inhibitors [letter]. Lancet 1998; 351:1958-9.
70. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors [letter]. Lancet 1998;351:1959.
71. Huang MB, Hunter M, Bond VC. Effect of extracellular human immunodeficiency virus type 1 glycoprotein 120 on primary human vascular endothelial cell cultures. AIDS Res Hum Retroviruses 1999; 15:1265-77.
72. Huang MB, Khan M, Garcia-Barrio M, Powell M, Bond VC. Apoptotic effects in primary human umbilical vein endothelial cell cultures caused by exposure to virion-associated and cell membrane-associated HIV-1 gp 120. J Acquir Immune Defic Syndr 2001; 27:213-21.
73. Park IW, Ullrich CK, Schoenberger E, Ganju RK, Groopman JE. HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation. J Immunol 2001; 167:2766-71.
74. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000; 18I(Suppl 3):S462-72.
75. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045-52.
76. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994; 24:416-20.
77. Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-in-fected individuals are associated with immune activation. J Acquir Immune Defic Syndr 1994; 7:1149-56.
78. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-30.
79. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348:702-10.
80. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myo-cardial infarction. N Engl J Med 2003; 349:1993-2003.
81. Zingmond DS, Kilbourne A, Justice AC, et al. Differences in symptom expression in older HIV-positive patients: the Veterans Aging Cohort 3 Site Study and HIV Cost and Service Utilization Study experience. J Acquir Immune Defic Syndr 2003;33(Suppl 2):S84-92.
82. Justice AC, McGinnis KA, Atkinson J, et al. Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS 2004; 18(Suppl 1): S49-59.